Empathx Clinical Research has joined hyperCORE International's global partner site network, expanding clinical research capabilities across multiple U.S. states and therapeutic areas. The Tampa Bay-based organization operates eight clinical trial sites across California, Florida, Massachusetts, Michigan, Missouri, and Texas, focusing on cardio-metabolic disease, central nervous system disorders, nephrology, and infectious disease research.
The partnership represents a significant expansion of hyperCORE International's network, which now includes more than 80 active trial sites across five countries. According to hyperCORE's website at https://www.hypercoreintl.com, the network has collectively completed over 7,000 studies involving more than 140,000 randomized participants through its partner organizations.
Empathx Clinical Research employs a hybrid model that includes both dedicated research centers and integrated sites embedded within specialized physician practices. This approach brings clinical research directly into existing care environments where patients already receive treatment, potentially increasing trial accessibility while supporting efficient study execution. The organization's geographic coverage and access to diverse patient populations provide sponsors with reliable solutions for clinical trial delivery.
CEO Dustin Owen emphasized that joining hyperCORE reflects a shared commitment to collaboration and quality among leading research site networks. "The partnership enhances our ability to work with sponsors to bring life-changing therapies to our communities," Owen stated. "Our added scale, geographic coverage, and access to diverse patient populations gives sponsors a reliable solution for delivering on clinical trials."
Nicholas Focil, President of hyperCORE International, noted that Empathx brings therapeutic expertise, geographic reach, and innovative site integration to the network. "Their approach to embedding research in clinical care aligns with hyperCORE's mission to expand patient access and deliver high-quality trials," Focil said. The network aligns independent organizations around harmonized operational frameworks that support consistent trial execution.
This development matters because it expands patient access to clinical trials in key therapeutic areas while potentially accelerating the development of new treatments. By integrating research into existing clinical care settings, the partnership addresses barriers to trial participation that often limit patient diversity and enrollment rates. The collaboration between established research networks could streamline trial operations and improve study quality through shared best practices and standardized procedures.
The implications extend to pharmaceutical sponsors seeking efficient trial execution, healthcare providers looking to offer research opportunities to patients, and patients themselves who gain increased access to potentially beneficial investigational therapies. As clinical research becomes more integrated into routine care settings, this partnership model may influence how future trials are conducted and accessed across the healthcare system.
